Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2 Genitourinary 1

Conditions

Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

Docetaxel 191 Gemcitabine 148 Prednisone 142 pembrolizumab 125 enzalutamide 119 Abiraterone Acetate 108 Nivolumab 107 Cisplatin 103 Magnetic Resonance Spectroscopy 100 Radiotherapy 95 Sunitinib 94 Leuprolide 91 Carboplatin 82 Specimen Handling 71 Androgen Antagonists 63 bicalutamide 60 Radiosurgery 60 Paclitaxel 59 Goserelin 59 Ipilimumab 57 Bevacizumab 57 apalutamide 53 Sorafenib 53 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51 Everolimus 49 cabozantinib 48 abiraterone 46 atezolizumab 45 cabazitaxel 43 durvalumab 42

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × budigalimab × Genitourinary × Clear all

NCT06632951 2025-08-11

LIVIGNO-3

AbbVie

Phase 2 Active not recruiting

Carcinoma, Transitional Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡